Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Under Armour Inc Class A trades at $4.63 (market cap $2.08B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.6× Under Armour Inc Class A's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Under Armour Inc Class A for 19 Days on average.
| SYRE | UA | |
|---|---|---|
Market Cap | $7.52B | $2.08B |
Volume | 1,441,031 | 2,142,599 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $7.88 |
52-Week Low | $22.18 | $3.96 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $6.52B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Under Armour (UA) trades at $4.76, down 0.63% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly earnings with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst sentiment is divided with 40% buy ratings, though recent news highlights revenue guidance cuts and competitive pressures.
The outlook remains challenging with persistent revenue declines and negative margins offset by attractive valuation multiples. Investment opportunity lies in potential turnaround execution, while risks include sustained consumer demand weakness and execution missteps in a highly competitive athletic apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
